Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Given Average Rating of “Hold” by Brokerages
Intra-Cellular Therapies, Inc. (NASDAQ:ITCI – Get Free Report) has received an average recommendation of “Hold” from the twelve research firms that are currently covering the firm, MarketBeat reports. Ten investment analysts have rated the stock with a hold recommendation and two have assigned a buy recommendation to the company. The average 12-month price target among […]
Intra-Cellular Therapies, Inc. (NASDAQ:ITCI – Get Free Report) has received an average recommendation of “Hold” from the twelve research firms that are currently covering the firm, MarketBeat reports. Ten investment analysts have rated the stock with a hold recommendation and two have assigned a buy recommendation to the company. The average 12-month price target among […]
